BioNTech (NASDAQ:BNTX) Given New $85.00 Price Target at TD Cowen

BioNTech (NASDAQ:BNTX) had its price objective decreased by TD Cowen from $98.00 to $85.00 in a research note published on Tuesday morning, Benzinga reports. TD Cowen currently has a hold rating on the stock.

Several other equities analysts have also weighed in on BNTX. HSBC upgraded shares of BioNTech from a hold rating to a buy rating in a report on Friday, August 2nd. BMO Capital Markets dropped their price objective on BioNTech from $123.00 to $122.00 and set an outperform rating on the stock in a research note on Tuesday, May 7th. HC Wainwright restated a buy rating and issued a $113.00 target price on shares of BioNTech in a research note on Thursday, August 1st. Hsbc Global Res raised BioNTech from a hold rating to a strong-buy rating in a research report on Friday, August 2nd. Finally, Evercore ISI assumed coverage on BioNTech in a report on Tuesday, May 14th. They issued an inline rating and a $100.00 price objective for the company. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and an average price target of $109.00.

BioNTech Stock Up 0.3 %

Shares of BNTX stock traded up $0.27 on Tuesday, hitting $80.80. The stock had a trading volume of 421,050 shares, compared to its average volume of 699,074. BioNTech has a 12-month low of $76.53 and a 12-month high of $125.83. The stock has a market cap of $19.21 billion, a price-to-earnings ratio of 161.60 and a beta of 0.23. The business has a 50 day moving average of $86.41 and a 200 day moving average of $90.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. BioNTech’s quarterly revenue was down 23.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.86) EPS. As a group, analysts expect that BioNTech will post -2.04 EPS for the current year.

Institutional Trading of BioNTech

Several institutional investors and hedge funds have recently bought and sold shares of BNTX. Dynamic Technology Lab Private Ltd increased its holdings in shares of BioNTech by 2.5% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock worth $492,000 after purchasing an additional 116 shares during the period. Covestor Ltd raised its holdings in shares of BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after acquiring an additional 133 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after acquiring an additional 150 shares during the last quarter. Arlington Capital Management Inc. grew its holdings in shares of BioNTech by 10.0% during the first quarter. Arlington Capital Management Inc. now owns 2,200 shares of the company’s stock worth $203,000 after purchasing an additional 200 shares in the last quarter. Finally, Midwest Professional Planners LTD. increased its position in shares of BioNTech by 7.2% in the first quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock worth $293,000 after purchasing an additional 212 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.